Views Of Turin - Italy

Views Of Turin - Italy

A Unicredit bank branch in the covered San Federico gallery in Turin, Italy on December 22, 2023. Photo by Laurent Coust/BACAPRESS.COM

  • Product Code
  • ILEA002126572
  • Registered date
  • 2023/12/22 00:00:00
  • Credit
  • Abaca Press / Kyodo News Images
  • Media source
  • Coust Laurent/ABACA
  • Media size
  • 4717 × 3538 pixel
  • Resolution
  • 300 dpi
  • Deployment size
  • 2.89(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    coust-doli

    coust-doli

    Illustration of Lysopaine boxe from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
      coust-doli

      coust-doli

      Illustration of Doliprane boxes from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
        coust-doli

        coust-doli

        Illustration of Doliprane boxes from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
          coust-doli

          coust-doli

          Illustration of Doliprane boxes from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
            coust-doli

            coust-doli

            Illustration of Doliprane tablet from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
              coust-doli

              coust-doli

              Illustration of Doliprane boxe from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
                coust-doli

                coust-doli

                Illustration of Doliprane boxe from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
                  coust-doli

                  coust-doli

                  Illustration of Doliprane boxes from the SANOFI Opella laboratory in Marseille, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Coust Laurent/ABACAPRESS.COM
                    Mazan Rape Trial - Avignon

                    Mazan Rape Trial - Avignon

                    Trial of Gisele Pelicot's former partner Dominique Pelicot who is accused of drugging her for nearly ten years and inviting strangers to rape her at their home in Mazan, a small town in the south of France, in Avignon, on September 16, 2024. A court in the southern town of Avignon is trying Dominique Pelicot, a 71-year-old retiree, for repeatedly raping and enlisting dozens of strangers to rape his heavily sedated wife in her own bed over a decade. Fifty other men, aged between 26 and 74, are also on trial for alleged involvement, in a case that has horrified France. The court proceedings, which runs until December, are open to the public at the request of Dominique Pelicot's ex-wife and victim. Photo by Laurent Coust/ABACAPRESS.COM
                      Mazan Rape Trial - Avignon

                      Mazan Rape Trial - Avignon

                      Gisele Pelicot and her lawyers Antoine Camus and Stephane Babonneau at the Avignon courthouse during the trial of her former partner Dominique Pelicot accused of drugging her for nearly ten years and inviting strangers to rape her at their home in Mazan, a small town in the south of France, in Avignon, France on September 16, 2024. A court in the southern town of Avignon is trying Dominique Pelicot, a 71-year-old retiree, for repeatedly raping and enlisting dozens of strangers to rape his heavily sedated wife in her own bed over a decade. Fifty other men, aged between 26 and 74, are also on trial for alleged involvement, in a case that has horrified France. The court proceedings, which runs until December, are open to the public at the request of Dominique Pelicot's ex-wife and victim. Photo by Laurent Coust/ABACAPRESS.COM